Karin Briner

Karin Briner is a medicinal chemist and pharmaceutical executive currently employed as the Vice President and Global Head of Chemistry at Novartis.

Karin Briner, Ph.D.
NationalitySwiss
Scientific career
Doctoral advisorAndrea Vasella
Other academic advisorsWilliam Roush

Education

Briner received her B.S. and Ph.D. degrees working at the University of Zurich with Professor Andrea Vasella.[1] She pursued postdoctoral studies at Indiana University with Prof. William Roush,[2] developing new methods to stereoselectively synthesize natural product glycosides.[3]

Career

After completing postdoctoral studies, Briner was hired at Eli Lilly & Company as a Senior Chemist in Infectious Diseases. Her work eventually evolved into central nervous system disorders such as depression, evidenced by multiple selective compounds against various serotonin receptors. She became the Managing Director of the Lilly Research Centre, UK, from 2007–2010. Briner was hired by the Novartis Institutes for Biomedical Research as the Global Head of Chemistry in 2011. Since that time, her team has been involved in the development of multiple new drug launches, for example nilotinib,[4] ceritinib, panobinostat, and Entresto.

Volunteer service

Briner was a founding member of the Innovative Medicines Initiative (IMI), and remains active in professional societies such as the European Federation for Medicinal Chemistry[5] and the American Chemical Society. She has delivered plenary talks at multiple scientific meetings.[6] She remains active in a mentoring capacity to incoming postdoctoral and Summer scholars at Novartis.[7]

Briner maintains an entry for the chemical production and purification of elemental lithium at EROS.[8]

gollark: 0.98 days but whatever.
gollark: The statistics panel says I've spent an entire day sneaking.
gollark: You can't escape.
gollark: I WILL join shortly.
gollark: Greetings, mortals.

References
  1. "Karin Briner, Ph.D. | Novartis". Novartis. Retrieved 2018-10-22.
  2. "Roush Research Personnel". www.scripps.edu. Retrieved 2018-10-22.
  3. Roush, William R.; Briner, Karin; Kesler, Brenda S.; Murphy, Megan; Gustin, Darin J. (January 1996). "Studies on the Synthesis of Aureolic Acid Antibiotics: Acyloin Glycosidation Studies". The Journal of Organic Chemistry. 61 (18): 6098–6099. doi:10.1021/jo960932e. ISSN 0022-3263. PMID 11667440.
  4. Ainsworth, Susan J. "Merck & Co., Novartis, And Arkema Chemists Honored For Discoveries | Chemical & Engineering News". cen.acs.org. Retrieved 2018-10-22.
  5. "EFMC Scientific Advisory Board". www.efmc.info. Retrieved 2018-10-22.
  6. Briner, Karin (2014). "Evolution of Medicinal Chemistry: Outlook and Opportunities". Retrieved 22 October 2018.
  7. "Karin Briner, Ph.D. | Novartis". Novartis. Retrieved 2018-10-22.
  8. Briner, Karin; Mathes, Brian M.; Ramón, Diego J.; Yus, Miguel (2014-10-20), "Lithium", Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd, pp. 1–8, doi:10.1002/047084289x.rl034.pub3, ISBN 9780470842898
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.